Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer
There is no definite evidence of a superior therapy for advanced non-small cell lung cancer
in elderly patients. With the exception of one known study, single agent erlotinib has not
been studied exclusively in the elderly and the combination of erlotinib and bevacizumab has
never been studied exclusively in the treatment naive elderly. This is an important
population that needs less toxic therapies.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy measure is progression free survival defined as the time from enrollment to documented progression of disease by radiologic imaging.
Scans to be done after every 2nd cycle of treatment
No
Hossein Borghaei, DO
Principal Investigator
Fox Chase Cancer Center
United States: Institutional Review Board
FER-TH-007
NCT00553800
March 2007
April 2015
Name | Location |
---|---|
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Grand View Hospital | Sellersville, Pennsylvania 18960 |
AtlantiCare Regional Medical Center | Pomona, New Jersey 08240 |
Pennsylvania Oncology Hematology Associates | Philadelphia, Pennsylvania 19107 |
Paoli Hospital | Paoli, Pennsylvania 19301 |
Fox Chase Virtua Health Cancer Program at Memorial | Mount Holly, New Jersey 08060 |
Abramson Cnacer Center, University of Pennsylvania | Philadelphia, Pennsylvania 19104 |